For research use only. Not for therapeutic Use.
Bersanlimab（Cat No.:I042157）is an investigational monoclonal antibody that targets the receptor CSF-1R (colony-stimulating factor 1 receptor), which plays a key role in the activation and survival of macrophages. CSF-1R is involved in the immune suppression within the tumor microenvironment, allowing cancer cells to evade detection. By inhibiting CSF-1R, bersanlimab aims to modulate the immune system, enhance anti-tumor immunity, and improve the effectiveness of cancer treatments. It is being studied in clinical trials for its potential to treat various cancers, particularly solid tumors, with the aim of improving patient outcomes.
| Catalog Number | I042157 |
| CAS Number | 1987854-08-9 |
| Purity | ≥95% |
